Blaze Therapeutics' publications are protected under copyright law by the designated author(s). If you would like to utilize the information found in any of listed publication, you are bound by copyright laws to cite all references.

 

Educational Publications

&

Resources

2019 Educational Guide - 6th Edition

download.png

Download the latest edition of the 2019 Educational Guide. While this publication is being provided to the public free of charge, it is protected by copyright laws and must be sited if referenced. If you are interested in partnering with Blaze Therapeutics to create scientifically accurate educational materials for the public, you may contact the Blaze team at info@blazetherapeutics.com.

Agriculture Improvement Act of 2018

download.png

The Agriculture Improvement Act of 2018 (also termed the Farm Bill Act of 2018) decriminalized hemp and all products derived from hemp, including CBD products. This legislation is directly responsible for the boom of the CBD industry.

DEA Public Letter 08/27/19

download.png

In this notice, the DEA announces that, as the result of a recent amendment to federal law, certain forms of cannabis no longer require DEA registration to grow or manufacture. The Agriculture Improvement Act of 2018, which was signed into law on Dec. 20, 2018, changed the definition of marijuana to exclude “hemp”—plant material that contains 0.3 percent or less delta-9 THC on a dry weight basis. Accordingly, hemp, including hemp plants and cannabidiol (CBD) preparations at or below the 0.3 percent delta-9 THC threshold, is not a controlled substance, and a DEA registration is not required to grow or research it. 

Small Entity Compliance Guide: Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements

Link icon.png

While the FDA does not currently classify CBD products as dietary supplements, manufacturers of CBD products derived from hemp operating under the Farm Bill Act of 2018 has an ethical duty to practice good manufacturing practices. Unfortunately, most manufacturers are not implementing GMP guidelines when manufacturing their products, which is why Blaze Therapeutics has implemented the Responsible Distribution model and the Unbiased Third Party Tested program for the Cannabis Industry. 

Not just another fish  in the sea.

  • MaxifyLife - Instagram
  • MaxifyLife LinkedIn

©Copyright 2019, Blaze Therapeutics. All Rights Reserved.

SUPPORT

ABOUT

STAY CONNECTED

Subscribe to our Mailing List

5250 Hwy 78

Suite 750-480

Sachse, TX

United States

info@blazetherapeutics.com

833-422-5293